ScandiDos (SDOS) Q2 2025 earnings summary

Executive summary

• Achieved improved profitability in the quarter, with positive operating results and net income of 0.5 Mkr compared to -1.2 Mkr in the same quarter last year.

• Cost reduction program from the previous year delivered full effect, lowering personnel and external costs.

• Asia, especially Japan, was the strongest region, while Europe remained cautious except for strong sales in Spain.

• Hospital Central de la Defensa Gómez Ulla in Madrid named as a reference center for ScandiDos and Delta4 products.

Financial highlights

• Net sales for the quarter were 16.2 Mkr, unchanged from the same quarter last year; six-month sales increased 3% to 28.8 Mkr.

• Gross margin for the quarter was 70% (down from 80%), impacted by a 0.6 Mkr inventory write-down; adjusted gross margin would have been 74%.

• EBITDA for the quarter was 0.9 Mkr (up from -0.5 Mkr); six-month EBITDA was 1.1 Mkr (up from -5.4 Mkr), mainly due to lower personnel costs.

• Net income for the quarter was 0.5 Mkr (up from -1.2 Mkr); six-month net income was -0.2 Mkr (up from -6.8 Mkr).

• Cash flow from operations for the quarter was -9.6 Mkr, negatively affected by increased receivables and reduced payables.

Outlook and guidance

• Continued focus on stable profitability and operational efficiency.

• Positive demand outlook for measurement systems, with strengthened partnerships and selective market investments.